Compare GVA & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GVA | BLLN |
|---|---|---|
| Founded | 1922 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.4B |
| IPO Year | 1995 | 2025 |
| Metric | GVA | BLLN |
|---|---|---|
| Price | $116.98 | $106.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $171.67 | $123.75 |
| AVG Volume (30 Days) | 410.1K | ★ 486.0K |
| Earning Date | 11-05-2026 | 08-05-2026 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | 47.33 | ★ 103.40 |
| EPS | N/A | ★ 0.48 |
| Revenue | ★ $1,762,965,000.00 | $305,112,000.00 |
| Revenue This Year | $22.01 | $49.16 |
| Revenue Next Year | $9.42 | $26.40 |
| P/E Ratio | ★ N/A | $241.80 |
| Revenue Growth | N/A | ★ 99.97 |
| 52 Week Low | $97.26 | $61.96 |
| 52 Week High | $162.08 | $150.44 |
| Indicator | GVA | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 48.66 |
| Support Level | $114.55 | $79.07 |
| Resistance Level | $129.07 | $108.50 |
| Average True Range (ATR) | 3.08 | 7.02 |
| MACD | 0.44 | 0.37 |
| Stochastic Oscillator | 54.74 | 30.57 |
Granite Construction Inc engages in the construction and development of various infrastructure projects on behalf of public and private clients in the United States. The company focuses on heavy civil infrastructure projects, including roads, highways, transit facilities, airports, bridges, dams, tunnels, and other infrastructure projects. In addition, the company performs site preparation and infrastructure services for residential development, energy development, and other facilities. The majority of revenue is derived from the company's Construction operating segment, and rest from Materials segment.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.